anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A man in his mid-40s presented to the colorectal surgery clinic with complaints of chronic perianal pain for over 20 years. He had episodes of urinary incontinence associated with pain. There were no other symptoms to suspect bowel pathology. On examination, he was found to have a tender mass in the retro-rectal plane without any evidence of rectal mucosal irregularity. He underwent an MRI of the pelvis, which showed a well-defined T2 hyperintense partly cystic lesion in the presacral region abutting the mesorectal fascia and a normal prostate gland. With a suspicion of a tailgut cyst or a duplication cyst, he underwent an excision of the presacral mass. Intraoperatively, there was a 2 × 2 cm well-defined firm, cystic lesion anterior to the fifth sacral vertebra and coccyx. The lesion was adherent to the mesorectum and was excised. On histopathology, there were features of muscular stroma and bilayered glandular epithelium with clear cytoplasm conclusive of a benign ectopic prostate.
The invention discloses a mycoplasma capricolum subsp. Capripneumoniae low-serum high efficiency medium. The mycoplasma capricolum subsp. Capripneumoniae low-serum high efficiency medium comprises the following components of PPLO broth, sodium pyruvate, lactose, tryptone, fresh yeast extract, L-glutamine, L-cysteine, lactoalbumin hydrolysate, horse serum, penicillin, phenol red, and deionized water; and the invention also provides a preparation method. The mycoplasma capricolum subsp. Capripneumoniae low-serum high efficiency medium has the beneficial effect that the serum content of the mycoplasma capricolum subsp. Capripneumoniae low-serum high efficiency medium is only 5%, which is 1/5-1/4 of the serum amount of the mediums in the prior art; in addition, the prepared semi-finished product bacteria liquid titer can reach 1010 CCU/ml, which is obviously higher than that of the medium in the prior art. The low-serum high efficiency medium used for culturing the mycoplasma capricolum subsp. Capripneumoniae is in favor of mitigating allergic stress reaction of heterogenous serum on goat, increases the biological safety, increases the live bacteria titer, and reduces the production cost.
Each participant will have their resting and active motor threshold measured using the transcranial magnetic stimulation (TMS) device. Participants will receive tACS for 10 minutes in the first session and tRNS in the second session.
The objectives of this study were to investigate the anti-fatigue effects of Paris polyphylla polysaccharide component 1 (PPPm-1) and explore its mechanisms. A mouse model of exercise-induced fatigue was established by weight-bearing swimming to observe the effects of different concentrations of PPPm-1 on weight-bearing swimming time. The anti-fatigue effect of PPPm-1 was determined by the effects of contraction amplitude, contraction rate, and diastolic rate of the frog gastrocnemius muscle in vivo before and after infiltration with 5 mg/mL PPPm-1. The effects of PPPm-1 on the contents of blood lactate, serum urea nitrogen, hepatic glycogen, muscle glycogen in the exercise fatigue model of mice, and acetylcholine (ACh) content and acetylcholinesterase (AChE) activity at the junction of the frog sciatic nerve-gastrocnemius under normal physiological, and Na+-K+-ATPase and Ca2+-Mg2+-ATPase activities of the frog gastrocnemius were determined by enzyme-linked immunosorbent assay (ELISA), to investigate the anti-fatigue mechanisms of PPPm-1. The results showed that PPPm-1 could significantly prolong the weight-bearing swimming time in mice (P < 0.01), decrease the contents of blood lactate and serum urea nitrogen, increase the contents of the hepatic glycogen and muscle glycogen of mice after exercise fatigue compared with those of the control group, and there was extremely significant difference in most indicators (P < 0.01). The 5 mg/mL of PPPm-1 could significantly promote the contraction amplitude, contraction rate, and relaxation rate of the gastrocnemius muscle in the frogs, and the content of ACh at the junction of the frog sciatic nerve-gastrocnemius (P < 0.01), but it had obvious inhibitory effetc on the activity of AChE at the junction of the frog sciatic nerve-gastrocnemius (P < 0.01). PPPm-1 could increase the Na+-K+-ATPase and Ca2+-Mg2+-ATPase activities of gastrocnemius in the frogs (for Ca2+-Mg2+-ATPase, P < 0.01). The above results suggested that the PPPm-1 had a good anti-fatigue effect, and its main mechanisms were related to improving endurance and glycogen reserve, reducing glycogen consumption, lactate and serum urea nitrogen accumulation, and promoting Ca2+ influx.
1530370 Citric acid by fermentation STANDARD MESSO DUISBURG GES FUR CHEMIETECHNIK mbH & CO 10 Sept 1976 [27 Sept 1975] 37564/76 Heading C2C [Also in Divisions C6 and F4]  A process for the fermentation of a nutrient substrate, exemplified by the fermentation of molasses by Aspergillus to produce citric acid, involves inoculating the substrate with the ferment in a germ-free chamber, allowing the ferment in a germination phase to extend over the entire surface of the substrate and effecting a fermentation phase wherein the fermentation product, citric acid is produced, and in the germination phase highly sterile air which has been pretreated through a coarse-fine-absolute filter, U-V sluice and superheated to about 120‹ C., is supplied in a small amount giving a slight excess pressure in the chamber whereby to prevent any extraneous infection from entering, and the fermenting substrate is independently heated by heaters, while in the exothermic fermentation phase the supply of highly sterile air and the heating are switched off and fresh, filtered unconditioned air is supplied to the chamber as cooling air so that the temperature of the fermenting substrate is kept substantially constant. The citric acid produced may be precipitated from solution as calcium citrate using milk of lime. Referring to the figure, the air conditioning system for use with germ-free chamber 2 consists essentially of an air system 4 for the germination phase including coarse filter 4-1, fan 4À2, fine filter 4À3, absolute filter 4À4, U-V sluice 4À5, superheater (to 120‹ C) 4À6 and valve 4À7, and a further air system 5 for the fermentation phase including coarse filter 5À1, fan 5À2, absolute filter 5À3 and valve 5À4. During the germination phase in which the fungus extends to cover the entire surface of the molasses substrate in the individual troughs 3, a small amount of highly sterile air is admitted from system 4 to produce an overpressure of from 5 mm. to 50 mm. water gauge in the chamber and the chamber is heated by heaters 6 fitted on each of the walls, and the cover and floor of the chamber. During the fermentation phase, in which the developed fungus exothermically ferments the molasses to produce citric acid, the chamber is supplied with sufficient fresh, filtered unconditioned air from system 5 to keep the temperature substantially constant, the air being vented through an exhaust valve 7. The air system 4 and heaters 6 are then not used.
The invention relates to a use of a Dendrobium officinale Kimura et Migo fluid extract antidote in treatment on organophosphorus pesticide poisoning. Stems and branches of Dendrobium officinale Kimura et Migo growing for more than 2 years are used as main raw materials, and through a series of production processes, the Dendrobium officinale Kimura et Migo fluid extract antidote is obtained. The Dendrobium officinale Kimura et Migo fluid extract antidote contains a large amount of unique medicinal ingredients of precious Chinese herbal medicine Dendrobium officinale Kimura et Migo, and a spectroscopy identification result shows that the Dendrobium officinale Kimura et Migo fluid extract antidote contains 18 novel compounds. The novel compounds has medicinal effects of tonifying stomach and promoting secretion of saliva or body fluid, nourishing yin and clearing heat, improving immunity, resisting hypoxia, improving irritability and resisting poisoning. The medicinal effects of the Dendrobium officinale Kimura et Migo fluid extract antidote are used for treating organophosphorus pesticide poisoning, and the Dendrobium officinale Kimura et Migo fluid extract antidote has effects of improving a patient detoxification capacity, improving patient antioxidant defense system functions, effectively clearing free radicals and toxins in the human body, protecting patients from free radical damage, reducing complication, improving a curing rate, promoting patient recovery and assisting treatment. The Dendrobium officinale Kimura et Migo fluid extract antidote creates a precedent at home and abroad and fills a domestic blank.
Pregnant people and their fetuses are vulnerable to adverse health outcomes from coronavirus 2019 disease (COVID-19) due to infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has been associated with higher rates of maternal mortality, preterm birth, and stillbirth. While SARS-CoV-2 infection of the placenta and vertical transmission is rare, this may be due to the typically longer time interval between maternal infection and testing of the placenta and neonate. Placental injury is evident in cases of SARS-CoV-2-associated stillbirth with massive perivillous fibrin deposition, chronic histiocytic intervillositis, and trophoblast necrosis. Maternal COVID-19 can also polarize fetal immunity, which may have long-term effects on neurodevelopment. Although the COVID-19 pandemic continues to evolve, the impact of emerging SARS-CoV-2 variants on placental and perinatal injury/mortality remains concerning for maternal and perinatal health. Here, we highlight the impact of COVID-19 on the placenta and fetus and remaining knowledge gaps.
PURPOSE:To obtain a mixed food having extremely high nutritive value even in a small amount and extremely useful as a tonic nourishing food by mixing edible mushrooms with Houttuynia cordata Thunb. in a suitable blending proportion. CONSTITUTION:Edible mushrooms, such as Pholiota nameko S. Ito et Imai, Lentinus edodes Sing. (SHIITAKE mushroom) or Grifola frondosa S.F. Gray, and Houttuynia cordata are preferably respectively dried, heat-treated and powdered. Both are then mixed in an optional proportion and one or two or more useful additives, such as amino acids, minerals, such as calcium or magnesium, and nutrient vitamins, as desired, are added. The resultant mixture is processed into a suitable form, such as paste or solid.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic agent for cancer readily transportable with a catheter and easily staying in affected parts.  <P>SOLUTION: The method for producing the therapeutic agent for the cancer is characterized as follows. A second aqueous solution prepared by dissolving an enzyme catalyzing hydrolysis of a carboxamide and an organic polymer gellable by a reaction with ingredients in a first aqueous solution or energy application from the outside, e.g. sodium carboxymethylcellulose or ammonium alginate is sprayed on the acidic or the neutral first aqueous solution obtained by dissolving a metal insolubilized in an alkaline solution such as calcium or iron and the carboxamide. The formed precipitate is then dried.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has manifested with respiratory symptoms and a spectrum of extra-pulmonary complications. Emerging evidence suggests potential impacts on the auditory and vestibular systems, but the extent and nature of these effects in recovered individuals remain unclear. This study aimed to investigate the prevalence and severity of vertigo and hearing impairment in individuals who have recovered from COVID-19 and to identify potential risk factors associated with these sensory symptoms. A cohort of 250 recovered COVID-19 patients was assessed. Standardized questionnaires, including the Dizziness Handicap Inventory and the Vertigo Symptom Scale, were used to evaluate vertigo. Hearing assessment was conducted using pure-tone audiometry, speech audiometry, tympanometry, and oto-acoustic emissions testing. Logistic regression analysis was performed to assess the association between COVID-19 severity and the occurrence of sensory symptoms, controlling for confounding variables such as age and comorbidities. Of the participants, 10% reported vertigo, varying severity. Hearing assessments revealed that most participants had normal hearing, with an average speech discrimination score of 94.6. Logistic regression analysis indicated a significant association between severe COVID-19 and an increased likelihood of vertigo (OR 2.11, 95% CI 1.02-4.35, P = .043) and hearing impairment (OR 3.29, 95% CI 1.60-6.78, P = .002). This study suggests a significant association between COVID-19 severity and vertigo and hearing impairment prevalence. The findings underscore the importance of sensory symptom assessment in the post-recovery phase of COVID-19, highlighting the need for comprehensive healthcare approaches to manage long-term sequelae.
Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate (which has the same active metabolite as VUMERITY) in the postmarketing setting. The onset has ranged from a few days to several months after initiation of treatment with dimethyl fumarate. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients. 

Elevations of hepatic transaminases (most no greater than 3 times the upper limit of normal) were observed during controlled trials with dimethyl fumarate [see Adverse Reactions (6.1)]. 

Obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior to treatment with VUMERITY and during treatment, as clinically indicated. Discontinue VUMERITY if clinically significant liver injury induced by VUMERITY is suspected.
Low-income Americans struggle to stay healthy in the face of real-life challenges such as housing insecurity or trauma. Two interventions show promise for promoting behavior change and improving health outcomes: digital health interventions coupled with financial incentives (DFI) and community health workers (CHWs). Yet, these interventions have limitations; DFI interventions have low uptake and high attrition among vulnerable populations, while CHW interventions are relatively resource intensive.

Investigators propose a 24-week randomized trial of a hybrid DFI/CHW intervention among a population of 150 low-income patients with diabetes. Participants will be randomized to one of three arms: 1) DFI intervention, 2) hybrid DFI/CHW intervention, 3) usual care. Participants assigned to DFI will receive a free wireless glucometer and be eligible for a lottery incentive if they use their glucometer. Participants assigned to the hybrid DFI/CHW intervention will receive the same glucometer and incentives. If they exhibit low adherence to self-monitoring or poor glucose control, they will also receive support from a CHW who would help patients to address underlying socioeconomic barriers and cope with setbacks. Investigators hypothesize that compared to usual care and DFI alone, the hybrid intervention will lead to more glucose self-monitoring and greater improvements in glycosylated hemoglobin.
Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
Obesity, a complex disorder with rising global prevalence, is a chronic, inflammatory, and multifactorial disease and it is characterized by excessive adipose tissue accumulation and associated comorbidities. Adipose tissue (AT) is an extremely diverse organ. The composition, structure, and functionality of AT are significantly influenced by characteristics specific to everyone, in addition to the variability connected to various tissue types and its location-related heterogeneity. Recent investigation has shed light on the intricate relationship between bone marrow stem cells and obesity, revealing potential mechanisms that contribute to the development and consequences of this condition. Mesenchymal stem cells within the bone marrow, known for their multipotent differentiation capabilities, play a pivotal role in adipogenesis, the process of fat cell formation. In the context of obesity, alterations in the bone marrow microenvironment may influence the differentiation of mesenchymal stem cells towards adipocytes, impacting overall fat storage and metabolic balance. Moreover, bone marrow's role as a crucial component of the immune system adds another layer of complexity to the obesity-bone marrow interplay. This narrative review summarizes the current research findings on the connection between bone marrow stem cells and obesity, highlighting the multifaceted roles of bone marrow in adipogenesis and inflammation.
During the first several weeks following lactation, nipple pain frequently prevents mothers from continuing breastfeeding. To evaluate the efficacy of using Photobiomodulation (PBM) versus anti-inflammatory topical cream, on inflamed nipple, and the effect on milk production. This study was carried-out on 50 breastfeeding women with nipple pain and fissure. Our patients were divided into two groups ; study group (Group I): 25 patients received 12 sessions of PBM using Diode laser for a period of 4 weeks, 3 sessions per week every alternative day, and controlled group (Group II): 25 patients used Anti-inflammatory topical cream. Regarding inflammatory signs in both groups, Group I showed a significant decrease in redness compared to Group II at the 3rd and 4th week, and a significant decrease in nipple fissure and pain at the 3rd week. There was a significant increase in milk amount reflected on the infant's weight. We concluded that PBM was more effective in decreasing nipple pain, inflammation and subsequently milk production and infant weight than topical anti-inflammatory creams.
In recent years it has been shown that many different brain stimulation techniques are effective in seizure reduction in epilepsy patients as well as in animal models of epilepsy. VNS is the method most often used with at least 45.000 patients implanted with this device worldwide. However, prediction of seizure outcome after VNS implantation is not possible in an individual patient so far. Recently, tDCS is increasingly used as a method to reduce seizure frequency in epileptic patients. Therefore it is hypothesized, that a positive effect after a single tDCS, in terms of short time seizure reduction and reduction of epileptic discharges in the EEG, could be predictive for epilepsy outcome after VNS implantation.

In the proposed multicenter prognostic study we test the predictive value of tDCS for each patient with refractory epilepsy 1 week up to 2 months before VNS implantation. The effects of tDCS will be verified via a 15 minutes long routine EEG examination, performed immediately before and after tDCS, together with seizure diary and seizure severity scale, assessed 1 month before and 1 week after tDCS. A 6 months long observation period will follow the VNS implantation. At the end of the 6 months period seizure diary and seizure severity scale of the last month will be performed to measure VNS therapy outcome. On the basis of the described variables, immediate up to 1 week long tDCS effects will be correlated to 6 months long VNS therapy outcome.
PURPOSE: The invention relates to a group of nonphenyl sulfonamide useful in prevention and treatment of diseases due to the destruction of connective tissues, such as arthritis, arteriosclerosis atka fish, restenosis and osteoporosis, by inhibiting matrix metalloproteases. CONSTITUTION: Matrix metalloproteases are natural enzymes found in most mammals and related to the destruction of connective tissues. The matrix metalloproteases include gelatinase A and B, stromellycin-1, fibroblast collagenase, neutrophil collagenase, matrillycin and other types of collagenase. The compounds are related to many diseases due to the destruction of connective tissues such as rheumatic arthritis, osteoarthritis, osteoporosis, periodontium disease, multiple arteriosclerosis, gingivitis, corneal subepithelia and stomach ulcer, arteriosclerosis atka fish, renal artery intinal proliferation resulting in restenosis, heart failure and tumor metastasis. The inventors have found a group of non-phenyl sulfonamides having very excellent inhibiting activities. The purpose of the invention is to provide the compounds, and treating methods of diseases mediated by metalloproteases by using their pharmaceutically allowable preparations. The invention provides non-phenyl sulfonamide which are inhibitors of metalloproteases. The compounds of the invention are the compounds of Formula (I), their pharmaceutically allowable salts and solvated materials.
Podocyte inflammatory injury has been indicated to play a pivotal role in the occurrence and development of diabetic nephropathy (DN). However, the pathogenesis of inflammation remains unclear. Recent researches have shown that GDF-15, a member of the transforming growth factor-β superfamily, were elevated under pathological conditions, such as myocardial ischemia, cancer, as well as inflammation. Here, we demonstrated that GDF-15 could alleviate podocyte inflammatory injury by modulating the NF-κB pathway. GDF-15 and other pro-inflammatory factors, such as TNF-α, IL-1β, and IL-6 were upregulated in the serum of HFD/STZ rat models. GDF-15 was also elevated in diabetic glomeruli and hyperglycemic stimuli treated-podocytes. The silence of GDF-15 in HG-stimulated podocytes further augmented inflammation and podocyte injury, while overexpression of GDF-15 significantly reduced the inflammatory response in podocytes. Mechanistically, we demonstrated that GDF-15 could inhibit the nuclear translocation of NF-κB through IKK and IκBα by interaction with ubiquitin ligase NEDD4L. Taken together, our data suggested a protective mechanism of elevated GDF-15 in DN through obstruction of ubiquitin degradation of IKK by inhibiting NEDD4L expression, thus decreasing the activation of NF-κB and relieving the inflammation. GDF-15 could serve as a potential therapeutic target for DN.
A folding warning marker includes three tubular stays each having first upper ends joined together by torsional coil springs. A flexible, brightly colored and reflective fabric cover is received over the stays. The torsional coil springs bias each adjacent pair of the three stays apart, forming isosceles triangles such that the fabric cover forms a pyramidal configuration. An apex region of the flexible cover is reinforced to withstand the stress induced by the torsional coil springs. Lower ends of each of the tubular stays are received in respective pockets formed on an interior surface adjacent the lower peripheral edge of the fabric cover. The stays may be manually forced into a parallel relation to form a compact closed position of the warning marker for storage and transportation purposes. The warning marker may be retained in the closed position by a securing strap or a storage tube.